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ABSTRACT: The oral fungal microbiota of 30 children with AIDS, of both genders, aged from two to six years, receiving
outpatient treatment, was evaluated and compared with that of a control group composed of 30 healthy subjects with
matching ages and genders. Virulence factors, such as exoenzyme production, and susceptibility to five antifungal
agents using an E-Test kit were evaluated. C. albicans predominated over other species in the AIDS group, showing a
higher production of proteinase and phospholipase when compared with that observed in the control group. In this
study few clinical manifestations of and low selectivity for C. albicans (23.3%) were observed in the AIDS group. The
enzymatic studies showed that 53.8% of the AIDS strains were strongly positive whereas only 33.3% of the non-AIDS
strains were positive. Amphotericin B was the most effective drug among the antifungal agents tested against C. albi-
cans. The frequency, selectivity and level of exoenzyme production by C. albicans suggest a higher pathogenicity in the
AIDS children than in the control children.
DESCRIPTORS: Acquired immunodeficiency syndrome; Child; Antifungal agents.
RESUMO: A microbiota fúngica bucal de 30 crianças com AIDS, de ambos os gêneros, com idades entre dois e seis
anos, recebendo atendimento ambulatorial, foi avaliada e comparada com a de um grupo controle constituído de 30
indivíduos saudáveis com idades e gêneros equivalentes. Fatores de virulência, tais como a produção de exoenzimas, e
a suscetibilidade dos microorganismos a cinco agentes antifúngicos, medida por meio de um kit E-Test, foram
avaliados. O microorganismo C. albicans predominou sobre outras espécies no grupo com AIDS, demonstrando uma
maior produção de proteinase e fosfolipase quando comparada com a produção observada no grupo controle. No grupo
com AIDS, foram observadas poucas manifestações clínicas de C. albicans, além de uma baixa seletividade para o
microorganismo (23,3%). Os estudos enzimáticos mostraram que 53,8% das linhagens no grupo com AIDS foram
fortemente positivas, ao passo que apenas 33,3% o foram no grupo controle. Dentre os agentes antifúngicos testados,
a anfotericina B foi a droga mais efetiva contra C. albicans. A freqüência, a seletividade e o nível de produção de
exoenzimas pelo microorganismo sugerem a ocorrência de uma maior patogenicidade nas crianças com AIDS do que
nas crianças do grupo controle.
DESCRITORES: Síndrome de imunodeficiência adquirida; Criança; Antimicóticos.
INTRODUCTION
The infection caused by HIV in children leads to
deep immunosuppression, has a shorter incuba-
tion period than in adults, and produces various
manifestations that include oral symptoms. These
occur earlier in children and facilitate the develop-
ment of opportunistic infections like fungal infec-
tions. The disease progression is faster and more
severe in children, as they possess an immature
immune system and are still undergoing develop-
ment5,8,9,13,23. The early diagnosis of lesions and
their complications is an important component in
the treatment of children, particularly considering
that candidiasis is one of the first signs of viral di-
sease progression4,11,15. Pseudomembranous candi-
diasis has a close correlation with the immune sta-
tus of the patient, especially in symptomatic
children, in whom reduced CD4+ leukocyte counts
lead to an increase in the frequency and severity of
AIDS-associated manifestations1,2,6,10.
Among the first reports concerning AIDS are ca-
ses of children exhibiting early and unexplained
immunodeficiencies associated with opportunistic
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infections, favored by intrauterine or post-birth
transmission10,16. Oral candidiasis and parotid en-
largement are considered to be important signs of
disease progression, guiding decisions during the
treatment of children with AIDS2,3,8,9,24.
In the present study, the frequency of yeasts,
their characteristics and levels of proteinase and
phospholipase production in children with AIDS
were evaluated and compared to those of 30 clini-
cally healthy control individuals without associa-
ted risk factors. The susceptibility of C. albicans to
five antifungal agents was also analyzed using a
commercial kit (E-Test).
MATERIAL AND METHODS
Patients
Among the patients treated and followed up by
the Section of Infectology, Santa Casa de Miseri-
córdia, São Paulo, SP, Brazil, we evaluated male
and female children aged between two and six ye-
ars, born to mothers with AIDS. The children exhi-
bited anti-HIV antibodies, which were detected
using the ELISA and Western Blot tests at 15
months of age. The results of recent laboratory
exams as well as past and present medical histori-
es were obtained from the hospital records. Using
these criteria, 30 symptomatic children with AIDS
receiving regular treatment with drugs like sulfa-
methoxazol + trimethoprim (Bactrin), and antire-
troviral agents such as zidovudine (AZT), dideoxy-
nosine (ddI), and/or 2-deoxy-3-tiacitidine (3TC or
Epivir) were selected. A control group composed of
30 children, healthy at examination and with mat-
ching ages and genders, was evaluated and com-
pared as to intraoral lesions. These children had
not received any blood transfusion and had no his-
tory of associated risk factors. The ELISA and Wes-
tern Blot tests were negative.
The Ethics Committee of the Santa Casa de Mi-
sericórdia of São Paulo, and that of the University
of São Paulo approved the procedures adopted in
the present study, which was initiated only after
the agreement and informed consent was obtained
from the parents and/or guardians of both groups
of children. They were examined under artificial il-
lumination. The extraoral examination consisted
of visual inspection and cervico-facial palpation,
performed initially to detect lymphadenitis and/or
enlarged parotid glands, as well as any facial lesi-
ons. The intraoral examination was carried out
using wooden spatulas for lip retraction. The cha-
racteristics and probable clinical diagnoses of all
oral manifestations were recorded. Protective mea-
sures were taken against infection dissemination
between patients.
Sampling of biological material
Sterile, alginated swabs (Cefar, Brazil), previ-
ously moistened in saline solution were used to
perform circular and rotatory movements at the
base of the upper and lower vestibules, on the floor
of the mouth, and/or on the tongue of each child to
collect material for yeast analysis. The material
was inoculated onto Petri dishes containing Sa-
bouraud-dextrose agar (Difco, Detroit, USA) and
100 µg/ml chloramphenicol (Park Davis, São Pau-
lo, Brazil).
Yeast isolation and identification
Inoculated plates were incubated at 25ºC up to
15 days. Subsequently, colonies were selected by
color, size, consistency, surface texture, borders,
brightness and topography, and the strains were
subcultured in test tubes containing the same cul-
ture medium. Isolated colonies were identified em-
ploying germ tube test, clamidoconidia formation,
micromorphological aspects, carbon and nitrogen
assimilation and sugar fermentation12.
Exoenzyme production
Exoenzyme (proteinase and phospholipase)
production tests and determination of their levels
were performed according to Price et al.17 and Ru-
chel et al.21 The standard strains (C. albicans
ICB-12A) were also used for comparison.
Susceptibility to antifungal agents
Candida strains were analyzed with regard to
their susceptibility to five antifungal agents, based
on minimum inhibitory concentrations (MIC) in
the E-Test7 (Biodesk, Solna, Sweden) performed
according to the manufacturers’ instructions. The
susceptibility to antifungal agents was based on
the criteria of Thornsberry, Sabath22 and Richard-
son, Warnock20 (seric levels). The five agents used
were: amphfotericin B, 5-fluorocytosine, flucona-
zole, itraconazole and ketoconazole. Standard
strains CBS (Central Bureau voor Schimmelcultu-
res) were used as controls.
Statistical analysis
Statistical analysis was performed on the data
for isolated yeasts using the chi-square test, the
Mann-Whitney test for proteinases and phospholi-
218
Bosco VL, Birman EG, Cury AE, Paula CR. Yeasts from the oral cavity of children with AIDS: exoenzyme production and antifungal
resistance. Pesqui Odontol Bras 2003;17(3):217-22.
pases, and the Kruskal-Wallis test for antifungal
evaluation.
RESULTS
Table 1 shows the distribution of children with
AIDS according to age and CD4+ cell count. There
were no children included in the range of no sup-
pression ( 1,000 cell/mm³); a percentage of 33.3%
(10/30) showed a moderate suppression (500-999
cell/mm³) and 66.6% (20/30) presented a severe
suppression (< 500 cell/mm³), although differen-
ces were not statistically significant (χ2 = 2.11). The
cultures were positive in all of the children (7/30)
with confirmed symptoms.
There was an association between candidiasis
and moderate suppression in only two of the seven
children (28.7%), while candidiasis and severe
suppression were associated in five out of the se-
ven children (71.4%).
With regard to yeast isolation, 83.3% (25/30) of
the samples collected from children with AIDS
gave positive results. Twenty-four samples were
positive for Candida albicans, one for Candida pa-
rapsilosis and one for Candida tropicalis, which
was associated with C. albicans (Graph 1).
The distribution of Candida species in children
with AIDS according to CD4+ cell count is shown
on Table 2. Positive cultures for Candida were
found in 34.6% (9/26) of the children with mode-
rate suppression, and in 57.6% (15/26) of those
with severe suppression. Among severely immuno-
suppressed children, 3.85% (1/26) showed a posi-
tive culture for Candida parapsilosis, and 3.85%
(1/26) for Candida tropicalis associated with C. al-
bicans. The AIDS group presented fungal selecti-
vity species among the positive samples. There was
a strong correlation between the presence of AIDS
and yeasts (χ2 = 7.89, p = 0.005).
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TABLE 1 - Distribution of children with AIDS according to age and CD4+ cell count.
Age
No suppression
( 1,000 cell/mm³)
Moderate suppression
(500-999 cell/mm³)
Severe suppression
(< 500 cell/mm³)
Total
2 to 4 years old
−
4 2 6
4 to 6 years old
−
6 18 24
Total 0 10 20 30
TABLE 2 - Candida species isolated from the oral cavity of children with AIDS, evaluated by CD4+ cell count.
Species
No suppression
( 1,000 cell/mm³)
Moderate suppression
(500-999 cell/mm³)
Severe suppression
(< 500 cell/mm³)
C. albicans - 9 15
C. parapsilosis - - 1
C. tropicalis* - - 1
*Associated with C. albicans.
GRAPH 1 - Distribution of yeasts
isolated from the oral cavity of
children with AIDS (one children was
positive for C. tropicalis associated
with C. albicans) and from the control
group.
In the control children, 10 samples were positi-
ve for yeasts: two for C. albicans, four for Candida
guilliermondii, one for Candida lusitaniae, two for
Rhodotorula rubra, and one for Aureobasidium pul-
lulans (Graph 1). The enzyme activity study sho-
wed that all yeasts isolated from the AIDS group
possessed proteinase activity. Fourteen samples
(53.8%) were strongly positive while 12 (46.1%) ex-
hibited positive activity. Nearly all samples 96.1%
(25/26) exhibited a strongly positive phospholipa-
se activity.
Among Candida strains isolated from the con-
trol group, 33.3% (3/10) presented a strongly posi-
tive proteinase activity, 44.4% (4/10) presented
positive activity, and 22.2% (2/10) were proteina-
se-negative. Phospholipase production, according
to the samples in this group, was strongly positive
in 66.6%, and only positive in 33.3%.
The Mann-Whitney test detected no statistically
significant differences in proteinase activity betwe-
en the control and the AIDS groups (U = 149.5;
U’ = 8; p = 0.2275), but revealed higher phospholi-
pase levels in the control group (U = 205;
U’ = −47.5; p = 0.0004).
The antifungal susceptibility analysis demons-
trated that some strains were resistant as the cha-
racteristic formation of the inhibition was not ob-
served. The minimum inhibitory concentration
test was 0.38 to 2.0 µg/ml for amphotericin B; 0.5
to 12.0 µg/ml for 5-fluorocytosine; 0.019 to 0.064
µg/ml for ketoconazole; 2.0 to 4.80 µg/ml for flu-
conazole and 0.012 to 8.0 µg/ml for itraconazole.
Considering that the main objective of this study
was to evaluate the antifungal susceptibility of
Candida species isolated from children with AIDS,
the E-Test was not performed with samples from
the control group.
Candida was more resistant to fluconazole
(80.76%), followed by itraconazole (42.30%), 5-flu-
orocytosine and ketoconazole (38.46%), and
amphotericin B (23.07%), with only six samples
showing resistance to the latter (Table 3).
Statistically significant differences were found
using the Kruskal-Wallis test when individual
comparisons were made among the antifungal
agents (t = 19.33; p = 0.0007). In these individual
comparisons (p < 0.01), the error rate was less
than 1%, indicating activity differences between
the antifungal agents.
DISCUSSION
The known number of pediatric AIDS cases
does not reflect the real impact of the epidemic.
The disease continues to grow and will soon be one
of the five major causes of child death, although
new drugs may revert this prediction. Since the
mouth is easily accessible for clinical examination,
it is one of the first areas to show signs of AIDS.
Clinical manifestations and various other aspects
must be examined, not only for diagnostic purpo-
ses, but also to delineate an adequate treatment
plan and prognosis1,3,5.
In our subjects, candidiasis was present with a
frequency similar to that reported by other resear-
chers6,18. Pseudomembraneous candidiasis predo-
minated over the erythematous type, both affec-
ting the children with moderate and severe
suppression. Candidiasis is considered to be a
prognostic factor and may indicate rapid disease
progression in children, differently from parotid
enlargement which is associated with a slower pro-
gression10.
Pseudomembraneous and erythematous candi-
diasis were detected on the tongue and/or palate,
with a higher frequency of the former, corrobora-
ting literature data5,18. Although some hypotheses
associate the presence of linear gingivitis with ery-
thematous candidiasis, this was not a finding in
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TABLE 3 - Susceptibility to antifungal agents of Candida albicans strains isolated from the oral cavity of children with
AIDS.
Antifungal agent
Sensitive Resistant
n % n %
Amphotericin B 20 76.9 6 23.1
5-Fluorocytosine 16 61.5 10 38.5
Ketoconazole 16 61.5 10 38.5
Fluconazole 5 19.2 21 80.8
Itraconazole 15 57.7 11 42.3
the group studied here25. The frequency of candidi-
asis has an important relationship with extrinsic
factors such as treatment and hospitalization.
Both may lead to low rates of clinical manifestati-
ons, which was demonstrated by the treatment gi-
ven to our patients and their subsequent outpati-
ent control.
Candida albicans was the predominant yeast
isolated from the oral cavity of the children with
AIDS. A statistically significant correlation was
found between AIDS and the presence of Candida,
which is important despite the lack of relevant cli-
nical candidiasis manifestations in most children
since many yeast infections show no clinical mani-
festations16.
A large number of C. albicans carriers have
been reported in some studies with children, in
whom this species is the most prevalent microor-
ganism, both in the oral cavity and in the esopha-
gus. However, a smaller number of C. albicans car-
riers among children, corroborated by our data,
reveal the prevalence of erythematous candidia-
sis14.
The children with AIDS in the present study ex-
hibited C. albicans almost exclusively as the pre-
dominant fungus, which may be attributed to the
antiviral drugs employed during treatment19. Ho-
wever, considering the secondary effects of such
drugs on the development of C. albicans, the con-
trol children showed a greater diversity of species.
Evaluation of the production of proteinase and
phospholipase, exoenzymes considered to be viru-
lence factors of Candida species, is relevant to the
expression of pathogenicity considering that C. al-
bicans is associated with various factors that re-
quire attention, especially when related to AIDS11.
High levels of phospholipase and proteinase, in ad-
dition to the selectivity of species present in the
AIDS group, provide conditions for greater adhe-
rence, colonization and development, facilitating
yeast multiplication. Proteinase expression seems
to be more active in isolates from HIV-infected
patients, a relevant aspect considering that anti-
retroviral agents may reduce exoenzyme produc-
tion13, a fact not confirmed in this study.
Inhibitors present in the saliva, and certain an-
tibodies (IgA) inhibit fungal adherence, and immu-
nodepression seems to favor greater pathogenicity,
especially of C. albicans, thus allowing its clinical
manifestation9,16. Few studies have examined these
aspects and they will not be discussed further in
the present study since different time periods,
drugs and conditions seen in adult AIDS groups
should also be considered.
Drugs effective against C. albicans strains were
studied using a commercial E-Test kit and the cri-
teria for susceptible resistance were followed ac-
cording to Richardson, Warrnock20 and Thorn-
sberry, Sabath22. In this study amphotericin B
seems to be the most effective. However, we point
out the secondary effects, contra-indications and
other problems regarding intravenous use to be li-
mitations to the use of this drug, in addition to the
lack of a topical preparation for dental use. Among
the azoles, itraconazol and ketoconazole are note-
worthy; fluconazole was the least effective due to
high resistance and the need for higher titers to
inhibit fungal growth. In vitro tests are important
markers, although in vivo studies, when perfor-
med, deserve greater consideration. The clinical
use of antifungal agents, in association with in vi-
tro tests, may contribute to a more effective treat-
ment of candidiasis, not always achieved with em-
pirical treatments or even with those based on well
controlled tests. The range of available drugs is
still very small and so the use of certain agents
cannot be avoided.
The development and use of new drugs and an
early diagnosis, associated to more detailed know-
ledge about infants with AIDS, have demonstrated
the effectiveness of certain treatments which have
resulted in a lower frequency of oral/facial and
bacterial manifestations. Progress in studies on
yeasts has been increasing, although new and
more effective therapeutics must be developed.
Our results show that the yeasts found in the
AIDS group were predominantly Candida albicans
while the control group exhibited a more diversity
of yeast species.
CONCLUSIONS
Proteinase and phospholipase production was
strongly positive and with a high activity in the
AIDS group, suggesting an increased pathogeni-
city in that group when compared to the control
group. According to the E-Test carried out in this
study, strains obtained from children with AIDS
were more susceptible to amphotericin B, followed
by 5-fluorocytosine and ketoconazole; however,
they were less susceptible to itraconazole and flu-
conazole. Differences were observed between the
AIDS and the control groups, although the drugs
used during ongoing treatment may have led to
changes in the behavior of the yeasts evaluated.
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